Traditional Chinese medicine composition for improving or treating hypertensive heart failure and application thereof
By adding motherwort and honeysuckle to Astragalus and Codonopsis pilosula granules, a new traditional Chinese medicine composition is formed, which solves the problem of poor treatment effect of hypertension and heart failure in the existing technology, significantly improves cardiac function and delays the pathological process.
Patent Information
- Application Number
- CN202411331964.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-24
- Publication Date
- 2024-11-12
AI Technical Summary
Existing Chinese herbal medicine compositions still need further optimization in the treatment of hypertension and heart failure, especially in improving the symptoms of heart failure caused by hypertension and slowing down the pathological process.
By adding motherwort and honeysuckle to the traditional Qi Shen granules which invigorate Qi and warm Yang, a new Chinese medicine composition is formed, which enhances the heat-clearing and detoxifying effects. In particular, the combination of motherwort and honeysuckle optimizes the detoxification treatment for symptoms such as edema and oliguria in patients with hypertension and heart failure.
It significantly improves cardiac function in patients with hypertension and heart failure, alleviates symptoms, reduces myocardial hypertrophy, slows down pathological progression, and the optimized formulation shows better therapeutic effects in basic experiments.
Smart Images

Figure CN118924811A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for improving or treating hypertensive heart failure and an application thereof. Background Art
[0002] Heart failure (HF) is the terminal stage of many cardiovascular diseases and a major disease that seriously endangers people's lives and health. Although the development of traditional Chinese and Western medicine HF treatment drugs has improved the clinical efficacy of HF, the prevalence of HF in China and around the world continues to rise.
[0003] Traditional Chinese medicine has a significant effect in treating heart failure. The premise and key to its breakthrough progress lies in the innovation of the understanding of the pathogenesis. The "Expert Consensus on the Diagnosis and Treatment of Chronic Heart Failure with Integrated Traditional Chinese and Western Medicine" points out that the pathogenesis of heart failure is the combination of "deficiency", "stasis" and "water". Although there are many prescriptions for the treatment of heart failure in traditional Chinese medicine, their prescriptions are generally based on traditional heart failure treatments such as invigorating qi, warming yang and promoting blood circulation. These heart failure treatments are effective in improving symptoms and improving the quality of life of patients, but they still need to be improved in delaying ventricular remodeling and improving long-term prognosis.
[0004] In recent years, the understanding of the etiology and pathogenesis of heart failure by traditional Chinese medicine has been continuously innovated, and toxic pathogens have become an important pathogenesis of the occurrence and development of heart failure. Many clinical patients with heart failure have clinical manifestations such as irritability, thirst, rapid pulse, red tongue and yellow fur, which are hot and related to inflammation, and acute heart failure or rapid deterioration of the condition occurs. Based on the clinical differentiation of toxic pathogens in heart failure, adding heat-clearing and detoxifying Chinese medicine to traditional treatment methods can effectively improve clinical efficacy and slow down the progression of heart failure. CN102258623B provides a combination of effective components of Chinese medicine for the treatment of chronic heart failure. The prescription is composed of six Chinese medicines: Astragalus, Salvia miltiorrhiza, Aconite, Scrophularia, Honeysuckle, and Licorice. It is combined with detoxifying Chinese medicine on the basis of traditional Chinese medicine for invigorating qi, promoting blood circulation and warming yang, and has the effects of invigorating qi, warming yang, promoting blood circulation and detoxifying. Clinical studies have shown that Qishen Granules have good clinical effectiveness and safety, and long-term use can significantly improve the cardiac function of patients with heart failure, alleviate heart failure symptoms, and improve the quality of life of patients. Water toxicity is a key pathological factor that distinguishes heart failure caused by hypertension from heart failure caused by other syndromes. Therefore, when combining different detoxification drugs in the optimized prescription for hypertension and heart failure, emphasis should be placed on "diuresis and detoxification" on the basis of invigorating qi and warming yang. Therefore, the detoxification treatment method of Qishen granules still needs to be further optimized. Summary of the invention
[0005] In view of the deficiencies of the prior art, the object of the present invention is to provide a Chinese medicine composition for improving or treating hypertensive heart failure and its application.
[0006] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:
[0007] In a first aspect, the present invention provides a traditional Chinese medicine composition for improving or treating hypertensive heart failure, wherein the raw materials for preparing the traditional Chinese medicine composition include astragalus, salvia miltiorrhiza, aconite root, motherwort, honeysuckle and roasted liquorice.
[0008] This application is aimed at the classification of heart failure caused by hypertension as the primary disease. According to the fact that the pathogenesis of hypertensive heart failure mainly revolves around water toxicity, it innovatively proposes to focus on specific primary diseases, that is, to further optimize the detoxification treatment method of Qishen Granule for hypertensive heart failure. Motherwort promotes blood circulation, promotes diuresis and reduces swelling, and has the effect of clearing away heat and detoxifying. Motherwort is compatible with honeysuckle, both of which enter the heart meridian. While the power of clearing heat and detoxifying is enhanced, it also has good effects of clearing the heart, promoting diuresis and reducing swelling. Compared with the compatibility of Scrophularia and honeysuckle, it can better improve the symptoms of edema, oliguria and other symptoms of patients with hypertensive heart failure.
[0009] Preferably, the raw materials for preparing the traditional Chinese medicine composition include, by mass, 28-34 parts of astragalus, 12-18 parts of salvia miltiorrhiza, 5-12 parts of aconite, 26-33 parts of motherwort, 7-13 parts of honeysuckle and 3-8 parts of licorice.
[0010] The mass fraction of the Astragalus can be selected from 28 parts, 29 parts, 30 parts, 31 parts, 32 parts, 33 parts, 34 parts, etc., the mass fraction of Salvia miltiorrhiza can be selected from 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, etc., the mass fraction of Aconite can be selected from 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, etc., the mass fraction of Leonurus can be selected from 26 parts, 27 parts, 28 parts, 29 parts, 30 parts, 31 parts, 32 parts, 33 parts, etc., the mass fraction of Honeysuckle can be selected from 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, etc., the mass fraction of Radix Glycyrrhizae Preparata can be selected from 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts, etc., and other specific point values within the above numerical range can be selected, which will not be repeated here one by one.
[0011] Preferably, the Chinese medicine composition is prepared by a method comprising the following steps: mixing the raw materials for preparation with water and boiling them, filtering, concentrating the filtrate, and drying.
[0012] Preferably, the decoction is performed 2-4 times and the decoction time is 50-70 minutes.
[0013] The number of decoctions can be selected as 2 times, 3 times, 4 times, etc., and the time can be selected as 50min, 52min, 54min, 56min, 58min, 60min, 62min, 64min, 66min, 68min, 70min, etc. Other specific point values within the above numerical range can be selected, so they will not be elaborated here.
[0014] Preferably, the mass of the water is 7-9 times the mass of the raw material, for example, 7 times, 7.2 times, 7.4 times, 7.6 times, 7.8 times, 8 times, 8.2 times, 8.4 times, 8.6 times, 8.8 times, 9 times, etc. Other specific point values within the above numerical range can be selected, and they will not be described here one by one.
[0015] Preferably, the concentration refers to concentrating the filtrate to a relative density of 2.6-2.8 at 60°C, for example 2.6, 2.62, 2.64, 2.66, 2.68, 2.7, 2.72, 2.74, 2.76, 2.78, 2.8, etc. Other specific point values within the above numerical range can be selected, and they will not be described one by one here.
[0016] In a second aspect, the present invention provides a use of the Chinese medicine composition for improving or treating hypertensive heart failure according to the first aspect in the preparation of a medicament for improving or treating hypertensive heart failure.
[0017] In a third aspect, the present invention provides a use of the Chinese medicine composition for improving or treating hypertensive heart failure according to the first aspect in the preparation of a drug for improving cardiac function.
[0018] In a fourth aspect, the present invention provides a use of the Chinese medicine composition for improving or treating hypertensive heart failure according to the first aspect in the preparation of a medicament for improving cardiac hypertrophy.
[0019] In a fifth aspect, the present invention provides a use of the Chinese medicine composition for improving or treating hypertensive heart failure according to the first aspect in the preparation of a drug for reducing pro-inflammatory factors in cardiac tissue.
[0020] Preferably, the dosage form of the drug includes tablets, pills, capsules, granules, granules, and oral liquids.
[0021] Preferably, the drug further comprises a pharmaceutically acceptable excipient.
[0022] Preferably, the auxiliary material comprises any one of an excipient, a diluent, a carrier, a flavoring agent, a binder or a filler, or a combination of at least two thereof.
[0023] Compared with the prior art, the present invention has the following beneficial effects:
[0024] The pharmaceutical composition of the present invention is a pure Chinese medicine preparation, which is a further formulation optimization of the representative Chinese medicine compound Qishen Granule for invigorating Qi and warming Yang, promoting blood circulation and detoxifying, targeting the primary disease of heart failure caused by hypertension, with emphasis on diuresis and detoxification. Based on the theory of "differentiation and treatment based on syndrome differentiation" of Chinese medicine compound, the drugs are rationally selected and matched, in order to improve the cardiac function and clinical symptoms of clinical patients and delay the pathological process of heart failure caused by hypertension, the primary disease, through the overall regulatory effect of the Chinese medicine compound. Basic experiments have confirmed that the optimized prescription for hypertension and heart failure can more effectively improve the cardiac function and myocardial hypertrophy of pressure-loaded TAC model mice compared with the original prescription of Qishen Granule. This result can provide partial theoretical support for the clinical promotion of the optimized prescription of Qishen Granule for hypertension and heart failure. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 This is the result of HL-I cell viability test.
[0026] Figure 2A It is the mRNA expression of Nppa, an indicator of myocardial hypertrophy in each group of cells.
[0027] Figure 2B The figure shows the mRNA expression of Myh7, an indicator of myocardial hypertrophy in each group of cells.
[0028] Figure 3A It is the mRNA expression of Nppa, an indicator of myocardial hypertrophy in each group of cells.
[0029] Figure 3B The figure shows the mRNA expression of Myh7, an indicator of myocardial hypertrophy in each group of cells.
[0030] Figure 4 The results of cardiac function test of each group of mice based on short-axis section using ultrasound M mode.
[0031] Figure 5A These are the LVEF test results of mice in each group.
[0032] Figure 5B These are the LVFS test results of mice in each group.
[0033] Figure 5C These are the LVIDd test results of mice in each group.
[0034] Figure 5D These are the LVIDs test results of mice in each group.
[0035] Figure 5E These are the LVEDV test results of mice in each group.
[0036] Fig. 5F These are the LVESV test results of mice in each group.
[0037] Fig. 6AThese are pictures of the hearts of mice in each group.
[0038] Figure 6B It is the heart / body weight ratio test result.
[0039] Fig. 7A This is the mRNA expression of Nppa, an indicator of myocardial hypertrophy, in each group of mice.
[0040] Figure 7B This is the mRNA expression of Nppb, an indicator of myocardial hypertrophy, in each group of mice.
[0041] Figure 7C The figure shows the mRNA expression of Myh7, an indicator of myocardial hypertrophy, in each group of mice.
[0042] Figure 8 Figure 3 is the HE staining of heart tissues of mice in each group.
[0043] Fig. 9 Figure 2 shows the WGA staining of heart tissues of mice in each group. DETAILED DESCRIPTION
[0044] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0045] Example 1
[0046] The present embodiment provides a traditional Chinese medicine composition, wherein the raw materials for preparing the traditional Chinese medicine composition include 30 parts of astragalus, 15 parts of salvia miltiorrhiza, 8 parts of aconite, 30 parts of motherwort, 10 parts of honeysuckle, and 6 parts of roasted liquorice.
[0047] The preparation method is as follows: the raw material is mixed with 8 times the mass of water and boiled for 3 times, each time boiling for 1 hour, the filtrate is combined, concentrated at 60°C to a relative density of 2.7, and dried to obtain the product.
[0048] This is recorded as the optimized prescription for hypertension and heart failure.
[0049] Comparative Example 1
[0050] This comparative example provides a traditional Chinese medicine composition, wherein the raw materials for preparing the traditional Chinese medicine composition include 30 parts of astragalus, 15 parts of salvia miltiorrhiza, 8 parts of aconite, 10 parts of Scrophularia, 10 parts of honeysuckle, and 6 parts of preparatory liquorice.
[0051] The preparation method is as follows: the raw material is mixed with 8 times the mass of water and boiled for 3 times, each time boiling for 1 hour, the filtrate is combined, concentrated at 60°C to a relative density of 1.2, and dried to obtain the product.
[0052] It was recorded as the original formula group of Qishen Granules.
[0053] Test Example 1
[0054] 1. CCK8 cell activity detection
[0055] To explore the difference in efficacy between the optimized drug Leonurus japonicus in the optimized prescription for hypertension and heart failure and the Chinese herbal medicine Scrophularia ningpoensis that was replaced in the original prescription, and to optimize the dosage of Leonurus japonicus, so as to evaluate the efficacy of the optimized prescription.
[0056] The original formula of Qishen Granules: 30g of Astragalus, 15g of Salvia miltiorrhiza, 8g of Aconitum, 10g of Scrophularia, 10g of Honeysuckle, and 6g of Roasted Licorice.
[0057] Optimized combination 1: Astragalus 30g, Salvia miltiorrhiza 15g, Aconitum 8g, Leonurus japonicus 10g, Honeysuckle 10g, and Glycyrrhiza uralensis 6g.
[0058] Optimized combination 2: Astragalus 30g, Salvia miltiorrhiza 15g, Aconitum 8g, Leonurus japonicus 20g, Honeysuckle 10g, and Licorice root 6g.
[0059] Optimized combination 3: Astragalus 30g, Salvia miltiorrhiza 15g, Aconitum 8g, Leonurus japonicus 30g, Honeysuckle 10g, and Glycyrrhiza uralensis 6g.
[0060] Optimized combination 4: Astragalus 30g, Salvia miltiorrhiza 15g, Aconitum 8g, Leonurus japonicus 40g, Honeysuckle 10g, and Glycyrrhiza uralensis 6g.
[0061] Optimized combination 5: Astragalus 30g, Salvia miltiorrhiza 15g, Aconitum 8g, Motherwort 40g, and Licorice 6g.
[0062] Optimized combination 6: Astragalus 30g, Salvia miltiorrhiza 15g, Aconitum 8g, Honeysuckle 40g, and Licorice root 6g.
[0063] The above-mentioned Chinese medicine compound was made into freeze-dried powder, and then prepared into a Chinese medicine compound with a concentration of 800 μg / mL by DMEM medium, filtered, and used for the subsequent cell intervention experiment. The effects of the original formula of Qishen granules and the optimized combination on the viability of HL-1 mouse cardiomyocytes were detected by CCK-8 method. HL-1 cells were seeded on 96-well plates, and 100 μL of about 2×10 3 After the cells were cultured until they were fully attached to the wall, they were set as the blank control group, the Qishen granule original formula (800μg / mL) group, the optimized combination 1 (800μg / mL) group, the optimized combination 2 (800μg / mL) group, the optimized combination 3 (800μg / mL) group, and the optimized combination 4 (800μg / mL) group. After 24h of intervention, CCK-8 working solution was added to the well plate, incubated, and the absorbance was read at a wavelength of 450nm in an ELISA reader. The experimental results are as follows Figure 1Compared with the control group, the original Qishen granule and the optimized combinations had no cytotoxicity to HL-I cells and had no significant effect on cell viability. The original Qishen granule and the optimized combinations 2 and 3 could improve the cell viability of HL-I, and the optimized combination 3 (30 g of Leonurus japonicus) was better than the optimized combination 2 (20 g of Leonurus japonicus).
[0064] 2. Cell real-time fluorescence quantitative PCR
[0065] A heart failure cell model was established by inducing HL-1 mouse cardiomyocytes with angiotensin II (AngII). The experiments were set up as blank control group, AngII group (1μM), Ang II (1μM) + Qishen granule original formula (800μg / mL) group, Ang II (1μM) + optimized combination 1 (800μg / mL) group, Ang II (1μM) + optimized combination 2 (800μg / mL) group, Ang II (1μM) + optimized combination 3 (800μg / mL) group, and Ang II (1μM) + optimized combination 4 (800μg / mL). After 24 hours of intervention, cellular RNA was extracted by RNAzol method and reverse transcribed into cDNA for real-time fluorescence quantitative PCR (qRT-PCR).
[0066] The expression levels of hypertrophy-related indicators Nppa and Myh7 were detected. PCR amplification was performed on a thermal cycler containing SYBRGreen (Takara, Japan) using a real-time fluorescence quantitative PCR detection system (Bio-Rad). Data analysis was performed using 2 -ΔΔCt Calculation was performed. The experimental results are shown in Figure 2. Compared with the control group, AngII intervention in cell modeling was successful. Compared with the AngII model group, the original Qishen granule and each optimized combination can reduce the expression levels of heart failure markers ANP and Myh7 in the AngⅡ-induced HL-1 myocardial hypertrophy model (P<0.05), and the improvement effect of each optimized combination is enhanced in a dose-dependent manner in accordance with Leonurus japonicus. Among them, the improvement effect of optimized combinations 3 and 4 is better than that of the original Qishen granule. Referring to the clinical dosage of Leonurus japonicus, combined with the above experimental results, we finally selected Leonurus japonicus 30g to optimize the formula of Qishen granules, that is, optimized combination 3 (replacing Scrophularia ningpoensis in the original Qishen granule formula with Leonurus japonicus 30g) is the optimized formula for hypertensive heart failure.
[0067] The above results preliminarily confirmed that the compatibility effect of 30 g of Leonurus japonicus and 10 g of Lonicera japonica in AngII-induced heart failure was better than that of Scrophularia ningpoensis and Lonicera japonica. To further verify the compatibility effect of the detoxifying traditional Chinese medicine pair in the optimized Qishen Granule formula, a heart failure cell model was constructed by inducing HL-1 mouse cardiomyocytes with AngII. A blank control group, an AngII group (1 μM), an Ang II (1 μM) + optimized formula for hypertensive heart failure (800 μg / mL) group, an Ang II (1 μM) + optimized combination 5 (800 μg / mL) group, and an Ang II (1 μM) + optimized combination 6 (800 μg / mL) group were set up. After 24 h of intervention, cell RNA was extracted and the expression levels of the hypertrophy-related indicators Nppa and Myh7 were detected. The experimental results are shown in Figure 3. Compared with the control group, the cell modeling with AngII intervention was successful. Compared with the AngII model group, the optimized formula for hypertensive heart failure and each optimized combination could reduce the expression levels of the heart failure markers ANP and Myh7 in the AngⅡ-induced HL-1 myocardial hypertrophy model (P<0.05), and the optimized formula for hypertensive heart failure had a better drug effect. Therefore, the optimized combination of adding 40 g of Leonurus japonicus or 40 g of Lonicera japonica alone was inferior to the formula of this application, proving that there is a drug compatibility relationship between the detoxifying medicine pair Leonurus japonicus and Lonicera japonica, and neither can be missing.
[0068] Test Example 2
[0069] Construction of animal model:
[0070] Male C57BL / 6 mice at 6 weeks of age, weighing 23±1 g, were purchased from the Guangdong Provincial Medical Experimental Animal Center (certificate number, SCXK (Guangdong) 2022—0002). All animal experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the Ethics Committee of Guangzhou University of Chinese Medicine.
[0071] A pressure overload-induced heart failure animal model was constructed by transverse aortic constriction (TAC). The mice were randomly divided into a sham operation group and a TAC model group. After one week of adaptive feeding and weighing, they were anesthetized by intraperitoneal injection of 0.5% sodium pentobarbital at a dose of 50 mg / kg. TAC modeling was performed on all mice except the sham operation group. In the TAC model group, transverse aortic constriction was performed, and in the sham operation group, sham operation was performed without aortic arch ligation. Two days after the operation, the blood flow at the site of transverse aortic constriction was detected by ultrasonic Doppler mode to judge the success of the TAC model. The mice with successful transverse aortic constriction were included in the model group.
[0072] Animal grouping and gavage:
[0073] Eight weeks after surgery, the cardiac function of mice in the sham operation group and the model group was tested by collecting long-axis ultrasound images of the papillary muscle level and the ventricle of the mice. Taking LVEF less than 50% after TAC as the inclusion standard for the heart failure model, the mice with LVEF less than 50% successfully modeled by TAC were grouped and randomly assigned to the TAC model group, Qishen granule group, low-, medium-, and high-dose groups of the optimized prescription for hypertension heart failure, and the positive control (perindopril) group, n=12.
[0074] Each group of mice was gavaged, and the gavage dose was calculated according to the equivalent dose for adults and the body surface area of the animals. The Qishen Granule group was gavaged with a medium dose of Qishen Granule (10.4 g / kg / d), and the low (6.5 g / kg / d), medium (13 g / kg / d), and high (26 g / kg / d) dose groups of the Hypertension Heart Failure Optimization Formula were gavaged at each concentration. The positive control group was gavaged with an equivalent dose of Perindopril (0.607 mg / kg / d). The sham operation group and the TAC model group were gavaged with normal saline. The gavage time was 4 weeks, and the gavage frequency was once a day.
[0075] Echocardiogram:
[0076] After intragastric administration, the cardiac function of mice in each group was detected by M-ultrasound based on the short axis section of the heart. All experimental data were collected and evaluated in a blinded manner. Figure 4 As shown. Echocardiography was performed using the Vevo2100 imaging system (Visual Sonics, Toronto, Canada). After 4 weeks of drug administration, mice in each group were anesthetized with 3% isoflurane before ultrasound, and ultrasound examination was performed at a maintenance concentration of 1.5%. At the end of diastole, cardiac parameters such as left ventricular ejection fraction (LVEF), left ventricular short-axis shortening fraction (LVFS), left ventricular systolic diameter (LVIDs), left ventricular diastolic diameter (LVIDd), left ventricular end-systolic volume (LVESV) and left ventricular end-diastolic volume (LVEDV) were calculated using the left ventricular internal diameter measured vertically on the ventricular short axis. All data were automatically obtained using the left ventricular trajectory measurement tool in the heart software package and the short axis (SAX) module in the Vero2100 analysis software.
[0077] Based on the M-ultrasound short-axis section, the cardiac parameters such as LVEF, LVFS, LVIDs, LVIDd, LVESV, and LVEDV of mice were measured to evaluate the cardiac contractile function. The experimental results are shown in Figure 5. The echocardiographic results showed that compared with the sham operation group, the cardiac function indicators LVEF and LVFS of the TAC model mice were significantly reduced; Chinese medicine intervention can effectively improve the cardiac function of the model mice (P<0.05); compared with the original Qishen granule, the high-dose group of the hypertension optimization prescription can more significantly improve the cardiac function of the TAC model mice (P<0.05).
[0078] Mouse body weight and heart weight measurement:
[0079] During the sampling process, the body weight and heart weight of each group of mice were weighed and photographed. Then the mice were anesthetized with 0.5% sodium pentobarbital, the skin was cut from the abdomen, and the muscle layer, chest cavity, and pleura were cut in sequence to expose and free the heart, which was then washed in PBS. After absorbing the water, the heart was placed on filter paper and weighed, and the weight was recorded.
[0080] The experimental results are shown in Figure 6. The results of the heart / body weight ratio experiment showed that compared with the sham operation group, the heart weight of the TAC model mice was significantly increased (P<0.05); Chinese medicine intervention can improve the cardiac hypertrophy of the model mice (P<0.05); compared with the original formula of Qishen Granule, the high dose of the hypertension optimized formula can more effectively improve the cardiac hypertrophy of the TAC heart failure model mice (P<0.05).
[0081] Real-time fluorescence quantitative PCR of mouse heart tissue:
[0082] Detection of mRNA expression levels of hypertrophy-related indicators Nppa, Nppb, and Myh7: Total RNA was extracted from mouse heart tissue using the RNAzol method, and reverse transcription was used to synthesize cDNA for real-time fluorescence quantitative PCR (qRT-PCR) detection. PCR amplification was performed on a thermal cycler containing SYBRGreen (Takara, Japan) using a real-time fluorescence quantitative PCR detection system (Bio-Rad). Data analysis was performed using 2 -ΔΔCt Perform calculations.
[0083] The experimental results are shown in Figure 7. Compared with the sham operation group, the mRNA expression levels of cardiac hypertrophy-related indicators in the TAC model group were significantly increased, and the original Qishen granule, the various doses of the hypertension heart failure optimization prescription, and the positive drug perindopril all had significant improvement effects (P<0.05). The high dose of the hypertension heart failure optimization prescription was significantly better than the original Qishen granule and perindopril.
[0084] Heart tissue staining:
[0085] Mouse heart tissues were collected, fixed with 4% paraformaldehyde, embedded in paraffin and sliced. HE staining was used to analyze cardiac pathological changes, Masson staining was used to analyze cardiac fibrosis, and WGA staining was used to analyze myocardial hypertrophy. The slices were then scanned and analyzed using a digital pathology slice scanning system (3D HISTEC, Pannoramic MIDI), and all slice data were quantitatively analyzed using ImageJ software.
[0086] HE staining results Figure 8The experimental results show that the myocardial cells of the control group mice are arranged relatively neatly, with clear and dense structures and less extracellular matrix; the heart volume of the TAC model group mice is significantly increased, the myocardial cells are arranged in disorder, the myocardial cells are twisted and hypertrophic, the intercellular spaces are increased, and there is inflammatory cell infiltration; compared with the original Qishen granule, the high-dose hypertension optimization formula can more significantly improve the pathological changes in the myocardial tissue structure. The WGA staining results are shown in Fig. 9 The experimental results showed that compared with the sham operation group, the area of cardiomyocytes in TAC model mice was significantly increased (P<0.05); Chinese medicine intervention can significantly reduce the hypertrophy of cardiomyocytes (P<0.05). Compared with the original formula of Qishen Granule, the high dose of the hypertension optimized formula can more significantly reduce the area of cardiomyocytes.
[0087] Statistical analysis methods:
[0088] The above samples conformed to normality and homogeneity of variance. The hypothesis test adopted one-way analysis of variance (One-Way ANOVA), and Turkey test was used as the pairwise comparison method.
[0089] Compared with the sham operation group, #P<0.05, ##P<0.01, ###P<0.0001, ####P<0.0001;
[0090] Compared with the model group, *P<0.05, **P<0.01, ***P<0.0001, ****P<0.0001.
[0091] Compared with the original Qishen Granule group, ΔP<0.05, ΔΔΔΔP<0.0001.
[0092] The above studies show that compared with the original formula of Qishen Granules, the optimized formula for hypertension and heart failure can more significantly improve the cardiac function and cardiac function parameters of TAC heart failure model mice caused by pressure load, and may have a better therapeutic effect on hypertension-induced heart failure.
[0093] The applicant declares that the present invention illustrates a Chinese medicine composition for improving or treating hypertensive heart failure and its application through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned embodiments, that is, it does not mean that the present invention must rely on the above-mentioned embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.
[0094] The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the technical concept of the present invention, a variety of simple modifications can be made to the technical solution of the present invention, and these simple modifications all belong to the protection scope of the present invention.
[0095] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not further describe various possible combinations.
Claims
1. A Chinese medicine composition for improving or treating hypertensive heart failure, characterized in that: The raw materials for preparing the traditional Chinese medicine composition include astragalus, salvia miltiorrhiza, aconite root, motherwort, honeysuckle and roasted liquorice.
2. The Chinese medicine composition for improving or treating hypertensive heart failure according to claim 1, characterized in that: The raw materials for preparing the traditional Chinese medicine composition include, by weight, 28-34 parts of astragalus, 12-18 parts of salvia miltiorrhiza, 5-12 parts of aconite, 26-33 parts of motherwort, 7-13 parts of honeysuckle and 3-8 parts of roasted liquorice.
3. The Chinese medicine composition for improving or treating hypertensive heart failure according to claim 1 or 2, characterized in that: The traditional Chinese medicine composition is prepared by a method comprising the following steps: mixing the raw materials and water and boiling them, filtering, concentrating the filtrate, and drying to obtain the traditional Chinese medicine composition.
4. The Chinese medicine composition for improving or treating hypertensive heart failure according to claim 3, characterized in that: The decoction is performed 2-4 times and the decoction time is 50-70 minutes.
5. Use of the Chinese medicine composition for improving or treating hypertensive heart failure according to any one of claims 1 to 4 in the preparation of a medicament for improving or treating hypertensive heart failure.
6. Use of the Chinese medicine composition for improving or treating hypertensive heart failure according to any one of claims 1 to 4 in the preparation of a medicament for improving cardiac function.
7. Use of the Chinese medicine composition for improving or treating hypertensive heart failure according to any one of claims 1 to 4 in the preparation of a medicament for improving cardiac hypertrophy.
8. Use of the Chinese medicine composition for improving or treating hypertensive heart failure according to any one of claims 1 to 4 in the preparation of a drug for reducing pro-inflammatory factors in cardiac tissue.
9. The use according to any one of claims 5 to 8, characterized in that: The dosage forms of the drug include tablets, pills, capsules, granules, granules, and oral liquids; Preferably, the drug further comprises a pharmaceutically acceptable excipient.
10. The use according to claim 9, characterized in that: The auxiliary materials include any one of excipients, diluents, carriers, flavoring agents, adhesives or fillers, or a combination of at least two of them.
